Bone Marrow Transplantation – Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
The prognosis of multiple myeloma (MM) continues to improve. Recent progress in therapies, using immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies, ha…
@HadidiSamer: #mmsm How to counsel patients about Cilta Cel using the data from CARTITUDE-4 and FDA ODAC meeting for earlier use With data of Cilta…
Second primary malignancies (SPMs) were reported in 536 out of 12,394 (4.3%) adverse event reports following CAR T cell therapies in the FDA Adverse Event…
Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cells condition considered as a pre-malignant entity that may evolve overtime to symptomatic
Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cells condition considered as a pre-malignant entity that may evolve overtime to symptomatic
This study aims to describe the treatment patterns, outcomes, health care utilization and symptom burden of triple class exposed (TCE) relapsed/refrac…
Emphasizing precise terminology in clinical studies may improve the transparency and accuracy of information presented at oncology conferences.
Blood Cancer Journal – Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Blood Cancer Journal – Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Blood Cancer Journal – Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
